acs 2
 
bar

program

  test
bar
 
 

ACS-WRAP:
Invasive Management of ACS

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This HealthWRAP is designed for These symposia are designed for all physician specialists who manage patients in the emergency department, coronary care unit, and cardiac catheterization laboratory. The focus will be on interventional cardiologists and emergency medicine specialists

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

rocheSupported by an independent educational grant from The Medicines Company, Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Faculty Disclosures:

Dr. Stone reports that he has received consulting fees from the Medicines Company, Boston Scientific, Guidant, Abbott, Volcano, St. Jude, and BMS. Imaging and lecture fees from the Medicines Company, Nycomed, Guidant, Medtronic, and Abbott.

Program Faculty:

Gregg W. Stone, MD, FACC
Professor of Medicine
Columbia University Medical Center
Director of Cardiovascular Research and Education
Center for Interventional Vascular Therapies
Chairman of the Cardiovascular Research Foundation
New York, New York

Educational Objectives:

  • As a result of this session, physicians will be able to assess and implement optimal antithrombotic strategies for patients with acute coronary syndromes (ACS).
  • As a result of this session, physicians will understand impact of specific pharmacologic agents on outcomes, including ischemic endpoints, bleeding, and mortality for patients with ACS.
  • As a result of this session, physicians are able to discuss the impact that new trials are likely to have on future management of patients with ACS.
  • As a result of this session, physicians will learn to apply AHA/ACC, ACCP, and other national guidelines in order to optimize therapy ACS.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

  test
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

 

 

 

Key Program Topics Include:
Abciximab
ACC/AHA
ACS
ACUITY
Acute Coronary Syndromes
Adenosine
Albumin
Anticoagulants
Anticoagulation
Antiplatelet
SYNERGY
Aspirin
Bivalirudin
Bleeding
Cath Lab
Catheterization
Streams
CLARITY–TIMI 28
Class I
Class IIa
Class IIb










Class III
Clopidogrel
CPK-MB
CREDO
CRUSADE
Double-bolus t-PA
Early Invasive
Early Invasive Therapy
Echocardiogram
Emergency Department
enoxaparin
Eptifibatide
EXTRACT
Fibrinolysis
Fibrinolytics
Fondaparinux
GIK
GP IIb/IIIa
GP IIb/IIIa inhibition
GP IIb/IIIa Inhibitors
Guidelines
Classes of Recommendations

GUSTO
Hirudin
Initial Conservativ
Initial Conservative Therapy
ischemic
LMWH
low-molecular-weight heparin
lytic
Magnesium
MI
Myocardial Infarction
Myoglobin
Net Clinical Benefit
nPA
NSTE ACS
Risk Stratify
Chest Pain
NSTEMI
PCI
OASIS-5
Oral GP IIb/IIIa

Parenteral Antiplatelet Therapy
Pexulizamab
Primary End Point
PSGL
REPLACE 2
Revascularization
rPA
STEMI
SYNERGY
Thienopyridine
TIMI
TIMI 25
Tirofiban
TNK
Troponin
UA
UA/NSTEMI
UFH
unfractionated heparin
Unstable Angina
Upstream